GlaxoSmithKline obtained the FDA's approval to market Tafinlar, or dabrafenib, and Mekinist, or trametinib, as single agents for treatment of advanced melanoma in patients carrying specific genes. The agency approved the use of Tafinlar in patients with the BRAF V600E mutation, while Mekinist was cleared for patients with either BRAF V600E or V600K.

Full Story:

Related Summaries